Hormone Resistant Prostate Cancer Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Mp70-11 reverse of docetaxel resistance in prostate cancer via notch signaling inhibition
Chemotherapeutic Docetaxel (Doc) is the standard of care for the hormone resistant prostate cancer (HRPC). However, many HRPC patients do not respond to Doc chemotherapy in a long-term treatment because the cancerous tissue acquires resistance to Doc treatment. The molecular mechanism underlying the development of Doc resistance in HRPC remains unclear. (Source: The Journal of Urology)
Source: The Journal of Urology - April 1, 2018 Category: Urology & Nephrology Authors: Qiu Shi, Xiang Tu, Qiang Wei, Lu Yang Tags: Prostate Cancer: Basic Research & Pathophysiology III Source Type: research

Virchow Node From Prostate Carcinoma by 18F-Choline PET/CT
We report a 75-year-old man with unsuspected involvement of Virchow node from prostate cancer observed using 18F-choline PET/CT. (Source: Clinical Nuclear Medicine)
Source: Clinical Nuclear Medicine - March 7, 2018 Category: Nuclear Medicine Tags: Interesting Images Source Type: research

Epigenetic changes induced by green tea catechins are associated with prostate cancer.
Abstract Prostate cancer is one of the most difficult cancers to treat especially when it becomes hormone resistant such as castrate resistant prostate cancer (CRPC) and subsequent metastatic CRPC. Apart from the genetic alterations in prostate cancer, epigenetic modifications also play an important role in the development and neoplastic progression of this disease. These include DNA methylation, histone modifications, and non-coding microRNAs. miRNAs are a novel class of small endogenous single-stranded non-coding RNAs of 19-25 nucleotides in length that typically silence gene expression. Considering the ...
Source: Current Molecular Medicine - December 18, 2017 Category: Molecular Biology Authors: Giudice A, Montella M, Boccellino M, Crispo A, D'Arena G, Bimonte S, Facchini G, Ciliberto G, Botti G, Quagliuolo L, Caraglia M, Capunzo M Tags: Curr Mol Med Source Type: research

GSE107438 25D3 and 1,25D3 target gene profiles in LNCaP
In this study, we investigated whole genome target gene profiles and intracellular behaviors of VDR after administration of 25D3 or 1,25D3 in prostate cancer LNCaP cells to elucidate the hormonal activity of 25D3. First, we confirmed that LNCaP cells possessed functional 25D3-VDR as well as 1,25D3-VDR signaling systems by qRT-PCR. By immunofluorescent examination of nuclear translocation, western blotting and most importantly, knockdown o f CYP27B1 and/or VDR after the introduction of the respective siRNA into these cells, we found that, just like 1,25D3, 10-7 M of 25D3, which is within its uppermost physiological concentr...
Source: GEO: Gene Expression Omnibus - December 1, 2017 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research

Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a.
Abstract Most prostate cancers initially respond to androgen deprivation therapy, but then progress from androgen-dependent to androgen-independent prostate cancers. In the present study, a differential cytotoxicity screen of hormone-resistant prostate cancer LNCaP-hr cells and the parental LNCaP-FGC cells against normal MRC5 fibroblast cells, identified a small molecule compound, Aristeromycin (a derivative of 3-deazaneplanocin A (DZNeP)). The molecular target was shown to be S-adenosylhomocysteine hydrolase (AHCY), which catalyzes reversible hydrolysis of S-adenosylhomocysteine (SAH) to adenosine and L-h...
Source: European Journal of Pharmacology - July 10, 2017 Category: Drugs & Pharmacology Authors: Uchiyama N, Tanaka Y, Kawamoto T Tags: Eur J Pharmacol Source Type: research

Incidental Leydig Cell Tumor in Patient with Hormone Resistant Prostate Cancer
Publication date: July 2017 Source:Urology Case Reports, Volume 13 Author(s): M. Sánchez Pérez, P. Jiménez Marrero, D. Kim Lee, M.P. Neumann, N. Jorge Pérez, C. Hernández Hernández, S. Hernández Escobar, R. Marrero Domínguez We hereby present the case of a 55 years old patient with clinical diagnosis of high-risk prostate cancer T2bN1Mo Gleason 9 (4 + 5) treated with androgen deprivation therapy and external beam radiotherapy. Despite treatment, castration levels were not achieved and clinical progression was evidenced by the appearance of bone metastases and progression of PSA. After several hormonal tre...
Source: Urology Case Reports - May 10, 2017 Category: Urology & Nephrology Source Type: research

[Comparison of the effect of multidrug resistance modifiers on prostate cancer, mouse lymphoma and colon cancer cells].
CONCLUSIONS: The tested phenothiazine and steroid derivatives showed potent anticancer activity, furthermore, the stereoisomerism of thioridazine did not play a role in the antitumor properties. Neither steroids nor thioridazine influenced apoptosis in hormone resistant cells. Orv. Hetil., 2016, 157(37), 1489-1495. PMID: 27615200 [PubMed - in process] (Source: Orvosi Hetilap)
Source: Orvosi Hetilap - August 31, 2016 Category: Journals (General) Authors: Csonka Á Tags: Orv Hetil Source Type: research

Adaptation and validation of an Italian version of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI).
CONCLUSIONS: The adaptation process showed that the PROSQOLI Italian version has high reliability and presents both convergent and discriminant validity. This version of the tool can be used to assess HRQoL in Italian men who underwent radical treatment for advanced prostate cancer. PMID: 27424974 [PubMed - in process] (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - July 21, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Neuronal trans‐differentiation in prostate cancer cells
CONCLUSIONThis study proposes that the later stages of PCa evolution involves neuronal trans‐differentiation, which would enable PCa cells to acquire independence from the neural axis, critical in primary tumors. Prostate. © 2016 Wiley Periodicals, Inc. (Source: The Prostate)
Source: The Prostate - July 12, 2016 Category: Urology & Nephrology Authors: Andrew Farach, Yi Ding, MinJae Lee, Chad Creighton, Nikki A. Delk, Michael Ittmann, Brian Miles, David Rowley, Mary C. Farach‐Carson, Gustavo E. Ayala Tags: Original Article Source Type: research

Neuronal trans ‐differentiation in prostate cancer cells
CONCLUSIONThis study proposes that the later stages of PCa evolution involves neuronal trans‐differentiation, which would enable PCa cells to acquire independence from the neural axis, critical in primary tumors. Prostate. © 2016 Wiley Periodicals, Inc. (Source: The Prostate)
Source: The Prostate - July 11, 2016 Category: Urology & Nephrology Authors: Andrew Farach, Yi Ding, MinJae Lee, Chad Creighton, Nikki A. Delk, Michael Ittmann, Brian Miles, David Rowley, Mary C. Farach ‐Carson, Gustavo E. Ayala Tags: Original Article Source Type: research

Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Authors: Jordan VC, Fan P, Abderrahman B, Maximov PY, Hawsawi YM, Bhattacharya P, Pokharel N Abstract The combined incidence and the extended disease course of breast and prostate cancer is a major challenge for health care systems. The solution for society requires an economically viable treatment strategy to maintain individuals disease free and productive, so as to avoid the fracture of the family unit. Forty years ago, translational research using the antiestrogen tamoxifen was targeted to estrogen receptor (ER) positive micrometastatic tumor cells and established the long-term antihormone adjuvant tre...
Source: Discovery Medicine - June 30, 2016 Category: Research Tags: Discov Med Source Type: research

Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.
Authors: Wang X, Zhang W, Yan Z, Liang Y, Li L, Yu X, Feng Y, Fu S, Zhang Y, Zhao H, Yu J, Jeong LS, Guo X, Jia L Abstract Salvage radiotherapy (SRT) is the first-line treatment for prostate cancer patients with biochemical recurrence following radical prostatectomy, and new specific radiosensitizers are in urgent need to enhance SRT effect. MLN4924 (also known as Pevonedistat), a specific inhibitor of NEDD8-activating enzyme, has recently entered phase I/II clinical trials in several malignancies. By inhibiting cullin neddylation, MLN4924 inactivates Cullin-RING ligases (CRL), which have been validated as...
Source: Oncotarget - May 27, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Stem Cells and the Role of ETS Transcription Factors in the Differentiation Hierarchy of Normal and Malignant Prostate Epithelium
Publication date: Available online 14 May 2016 Source:The Journal of Steroid Biochemistry and Molecular Biology Author(s): Leanne K. Archer, Fiona M. Frame, Norman J. Maitland Prostate cancer is the most common cancer of men in the UK and accounts for a quarter of all new cases. Although treatment of localised cancer can be successful, there is no cure for patients presenting with invasive prostate cancer and there are less treatment options. They are generally treated with androgen-ablation therapies but eventually the tumours become hormone resistant and patients develop castration-resistant prostate cancer (CR...
Source: The Journal of Steroid Biochemistry and Molecular Biology - May 13, 2016 Category: Biochemistry Source Type: research

False-positive diagnosis of disease progression by magnetic resonance imaging for response assessment in prostate cancer with bone metastases: A case report and review of the pitfalls of images in the literature.
Authors: Yu YS, Li WH, Li MH, Meng X, Kong LI, Yu JM Abstract Bone metastases are common in prostate cancer. However, differentiating neoplastic from non-neoplastic alterations of bone on images is challenging. In the present report, a rare case of bone marrow reconversion on magnetic resonance imaging (MRI) assessment, which may lead to a false-positive diagnosis of disease progression of bone metastases in hormone-resistant prostate cancer, is presented. Furthermore, a review of the literature regarding the pitfalls of images for response assessment, including the 'flare' phenomenon on bone scintigraphy,...
Source: Oncology Letters - January 21, 2016 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
Abstract Key issues for prostate cancer patients are the detection of recurrent disease and the treatment of metastasized cancer. Early detection is a major challenge for all conventional imaging modalities. Furthermore, therapy of patients with hormone-resistant tumor lesions presents a major clinical challenge. Because the prostate-specific membrane antigen (PSMA) is frequently overexpressed in prostate cancer, several PSMA-targeting molecules are under development to detect and treat metastatic castration-resistant prostate cancer (mCRPC). mCRPC represents a situation where cure is no longer achievable ...
Source: Clinical Cancer Research - January 1, 2016 Category: Cancer & Oncology Authors: Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M Tags: Clin Cancer Res Source Type: research